Evidence map›Paper›PMID 35176205›Full record

ReviewThe FEBS journal2023

ERK1/2-RSK regulation of oestrogen homeostasis.

Eric B Wright, Deborah A Lannigan

Open access · hybridAbstract readReview
In one paragraph

Review in The FEBS journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Eric B WrightBiomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-9575-6801
Deborah A LanniganBiomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-8380-9240
Vanderbilt University · US

Funding

RSK2 in Estrogen Receptor Positive (ER+) Breast CancerR01CA213201 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH, SULIKOWSKI, GARY ALLEN · 2018 to 2022
$1.8M
Estrogen Receptor HomeostasisR01DK113423 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH · 2018 to 2022
$1.6M
NCI NIH HHS R01 CA213201NIDDK NIH HHS R01 DK113423NIH HHS CA213201NIH HHS DK113423
6 · The paper itself

Abstract

The molecular mechanisms regulating oestrogen homeostasis have been primarily studied in the mammary gland, which is the focus of this review. In the non-pregnant adult, the mammary gland undergoes repeated cycles of proliferation and apoptosis in response to the fluctuating levels of oestrogen that occur during the reproductive stage. Oestrogen actions are mediated through the steroid hormone receptors, oestrogen receptor α and β and through a G-protein coupled receptor. In the mammary gland, ERα is of particular importance and thus will be highlighted. Mechanisms regulating oestrogen-induced responses through ERα are necessary to maintain homeostasis given that the signalling pathways that are activated in response to ERα-mediated transcription can also induce transformation. ERK1/2 and its downstream effector, p90 ribosomal S6 kinase (RSK), control homeostasis in the mammary gland by limiting oestrogen-mediated ERα responsiveness. ERK1/2 drives degradation coupled ERα-mediated transcription, whereas RSK2 acts as a negative regulator of ERK1/2 activity to limit oestrogen responsiveness. Moreover, RSK2 acts as a positive regulator of translation. Thus, RSK2 provides both positive and negative signals to maintain oestrogen responsiveness. In addition to transmitting signals through tyrosine kinase receptors, ERK1/2-RSK engages with hedgehog signalling to maintain oestrogen levels and with the HIPPO pathway to regulate ERα-mediated transcription. Additionally, ERK1/2-RSK controls the progenitor populations within the mammary gland to maintain the ERα-positive population. RSK2 is involved in increased breast cancer risk in individuals taking oral contraceptives and in parity-induced protection against breast cancer. RSK2 and ERα may also co-operate in diseases in tissues outside of the mammary gland.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaEstrogensFemaleHedgehog ProteinsHumansMAP Kinase Signaling SystemPregnancyReceptors, EstrogenRibosomal Protein S6 Kinases, 90-kDaEstrogen Receptor alphaEstrogensHedgehog ProteinsReceptors, Estrogenribosomal protein S6 kinase, 90kDa, polypeptide 3Ribosomal Protein S6 Kinases, 90-kDaERK1/2ERαmammary glandMAPKoestrogenp90 ribosomal S6 kinasep90RSKRSK2

Identifiers

PMID35176205
PMCPMC9381647
OpenAlexW4213102774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.